<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02976116</url>
  </required_header>
  <id_info>
    <org_study_id>2016-013-00CH1</org_study_id>
    <nct_id>NCT02976116</nct_id>
  </id_info>
  <brief_title>A Phase II Study of Fruquintinib in Combination With Gefitinib in Patients With Advanced Non-small Cell Lung Cancer</brief_title>
  <official_title>Fruquintinib in Combination With Gefitinib as First-line Therapy in Patients With Advanced Non-squamous Non-small-cell Lung Cancer Harboring Activating EGFR Mutations : a Single-arm, Multicenter, Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hutchison Medipharma Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hutchison Medipharma Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Fruquintinib in combination with Gefitinib as first-line therapy in patients with advanced
      non-squamous non-small-cell lung cancer harboring activating EGFR mutations : a single-arm,
      multicenter, phase II study
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This phase II trial will evaluate the combination of fruquintinib and gefitinib in advanced
      NSCLC. The endpoint will be to evaluate the efficacy and safety of the combination.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2016</start_date>
  <completion_date type="Actual">June 28, 2019</completion_date>
  <primary_completion_date type="Actual">June 28, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>tumor objective response rate</measure>
    <time_frame>Patients will be followed until study completion, an average of 1 year</time_frame>
    <description>Occurrence of completed response or partial response after treatment, assessed by RECIST 1.1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>Each patient will be followed for 30 days after the last dose</time_frame>
    <description>Number of participants with treatment-related adverse events as assessed by CTCAE v4.03</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>Patients will be followed until study completion, an average of 1 year</time_frame>
    <description>The duration from first dose to first documented progression or death from any cause, whichever came first, assessed by RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration control rate (DCR)</measure>
    <time_frame>Patients will be followed until study completion, an average of 1 year</time_frame>
    <description>Occurrence of completed response, or partial response, or stable disease, assessed by RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to response (TTR)</measure>
    <time_frame>Patients will be followed until study completion, an average of 1 year</time_frame>
    <description>the period from the date of first dose to the date when the criteria for complete response or partial response was first measured</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response （DoR）</measure>
    <time_frame>Patients will be followed until study completion, an average of 1 year</time_frame>
    <description>Duration from first documented completed response or partial response to first documented progression or death from any cause, whichever came first</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>NSCLC</condition>
  <arm_group>
    <arm_group_label>Fruquintinib &amp; Gefitinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: Fruquintinib and Gefitinib</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fruquintinib</intervention_name>
    <description>Fruquintinib will be administered orally once daily from Day 1 to Day 21 per 28-day cycle until disease progression or unacceptable toxicity</description>
    <arm_group_label>Fruquintinib &amp; Gefitinib</arm_group_label>
    <other_name>HMP-013</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gefitinib</intervention_name>
    <description>Gefitinib will be administered orally once daily per 28-day cycle or unacceptable toxicity</description>
    <arm_group_label>Fruquintinib &amp; Gefitinib</arm_group_label>
    <other_name>Iressa</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed Informed Consent Form.

          -  Age between 18 to 75 years old.

          -  Histologically or cytological documented stage IIIB/IV non-squamous non-small cell
             lung cancer patients who have never received systematic treatment for the late-stage
             disease.

          -  ECOG 0-1

          -  Patients must have measurable lesions

        Exclusion Criteria:

          -  Prior systematic treatment for the advanced NSCLC

          -  Absolute neutrophil count (ANC) &lt; 1.5×10^9 /L, or platelet count &lt; 100 ×10^9/L, or
             hemoglobin &lt; 9 g/dL

          -  Total bilirubin &gt; 1 ULN; SGOT (AST), SGPT (ALT), &gt; 1.5 ULN; for patient with liver
             metastasis，AST or ALT &gt; 3 ULN

          -  Known HIV positive

          -  Hypersensitivity to either of the investigation drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hongyan Yin</last_name>
    <role>Study Director</role>
    <affiliation>Hutchison MediPharma Ltd</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shanghai Chest Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Hospital of Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>November 17, 2016</study_first_submitted>
  <study_first_submitted_qc>November 24, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 29, 2016</study_first_posted>
  <last_update_submitted>November 14, 2019</last_update_submitted>
  <last_update_submitted_qc>November 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Fruquintinib</keyword>
  <keyword>NSCLC</keyword>
  <keyword>1st line</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gefitinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

